. 2023 Jul 5;12(8):e220542. doi: 10.1530/EC-22-0542
This work is licensed under a Table 1.
Clinical characteristics and serum TMAO levels.
| control group (n = 33) | NDKD group (n = 73) | DKD group (n = 35) | F/X²/Z | P | |
|---|---|---|---|---|---|
| Age (year) | 52.00 ± 12.69 | 51.58 ± 12.52 | 55.86 ± 14.17 | 1.356 | 0.261 |
| Male | 60.6% (20/33) | 65.8% (48/73) | 77.1% (27/35) | 2.294 | 0.318 |
| BMI (kg/m²) | 22.18 ± 2.83 | 25.31 ± 3.42a | 23.86 ± 3.99 | 9.651 | 0.000d |
| Diabetes duration (year) | NA | 5.0 (1.0, 10) | 10 (4.25,16.0)b | −2.752 | 0.006d |
| Hypertension (%) | NA | 32.9% (24/73) | 51.4% (18/35)b | 4.210 | 0.040b |
| BUN (mmol/L) | 4.6 (3.93, 5.55) | 5.11 (4.24, 6.07) | 5.83 (4.93, 7.30)a,b | 9.892 | 0.007e |
| UA (μmol/L) | 313 (282, 413.5) | 305 (235, 358.5) | 370 (309, 407)b | 8.525 | 0.014b |
| FPG (mmol/L) | 5.39 (5.10, 5.80) | 8.0 (6.68, 10.13)a | 7.85 (6.52, 9.55)a | 46.249 | 0.000d |
| HbA1c (%) | NA | 9.2 (7.0, 11.05) | 9.3 (7.0,10.3) | -0.420 | 0.674 |
| SCR (μmol/L) | 70.0 (56.95, 78.1) | 66 (55.1, 76.0) | 75.9 (63.0, 96.0)b | 9.690 | 0.008c |
| eGFR (mL/min•1.73 m²) | 102.32 ± 22.31 | 113.14 ± 27.38 | 95.99 ± 41.64b | 4.10 | 0.029b |
| TMAO (μmol/L) | 0.25 (0.16, 0.46) | 0.30 (0.17, 0.48) | 0.44 (0.25, 1.07)a,b | 11.789 | 0.003c |
vs control group, aP < 0.05, vs NDKD group,bP < 0.05 vs NDKD group, cP < 0.01, vs NDKD group dP < 0.001.